Cassava Sciences Completes Enrollment For Pivotal Phase 3 Program Of Simufilam In Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences has completed enrollment for its Phase 3 program of Simufilam in Alzheimer's disease. The program includes two trials with 1,929 patients. Top-line results for the 52-week trial are expected by the end of 2024, and for the 76-week trial by mid-2025.
November 06, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cassava Sciences has completed enrollment for its Phase 3 trials of Simufilam. The results of these trials could significantly impact the company's future.
The completion of enrollment for the Phase 3 trials is a significant milestone for Cassava Sciences. However, the impact on the stock price will depend on the results of these trials, which are expected in 2024 and 2025. Therefore, the short-term impact is neutral, but the long-term impact could be significant.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100